

Applicant: Phillips et al.  
Application Serial No. 09/735,363  
Amendment and Response to Office Action  
Page 2 of 7

### AMENDMENTS TO THE CLAIMS

Please cancel ~~Claim 6~~.

#### *Listing of Claims*

Claim 1. (Previously amended) A composition, comprising a 2 to 20 base 3'-OH, 5'-OH synthetic phosphodiester nucleotide sequence selected from the group consisting of  $(G_xT_y)_n$ ,  $(T_yG_x)_n$ ,  $a(G_xT_y)_n$ ,  $a(T_yG_x)_n$ ,  $(G_xT_y)_nb$ ,  $(T_yG_x)_nb$ ,  $a(G_xT_y)_nb$ , and  $a(T_yG_x)_nb$ , wherein x and y is an integer between 1 and 7, n is an integer between 1 and 12, a and b are one or more As, Cs, Gs or Ts, and a pharmaceutically acceptable carrier, wherein the composition is useful for inducing a response in an animal having cancer when administered in an effective amount to the animal having cancer.

---

Claim 2. (Currently amended) The composition of ~~claim~~  
Claim 1, wherein the sequence is between 2 and 15 bases.

B<sup>1</sup>  
Claim 3. (Currently amended) The composition of ~~claim~~  
Claim 2, wherein the sequence is between 2 and 10 bases.

Claim 4. (Currently amended) The composition of ~~claim~~  
Claim 3, wherein the sequence is between 2 and 7 bases.

Claim 5. (Currently amended) The composition of ~~claim~~  
Claim 1, further comprising a chemotherapeutic agent.

---

Claim 6. (~~Cancelled~~)

*Applicant: Phillips et al.*  
*Application Serial No. 09/735,363*  
*Amendment and Response to Office Action*  
*Page 3 of 7*

Claim 7. (Previously amended) The composition of Claim 1, wherein the phosphodiester nucleotide sequence is selected from the group consisting of SEQ ID NOs: 7-18, 23-47, 50-66, and 81-83.

Claim 8. (Previously amended) The composition of Claim 1, wherein the phosphodiester nucleotide sequence is selected from the group consisting of SEQ ID NOs: 7-10, 22-65, 70-75, 79 and 80.

Claim 9. (Cancelled)

Claim 10. (Previously amended) The composition of Claim 5, wherein the chemotherapeutic agent is selected from the group consisting of antimetabolites, alkylating agents and hormone antagonists.

Claims 11-20. (Withdrawn)

Claim 21. (Cancelled)

Claims 22-28. (Withdrawn)

Claims 29-41. (Cancelled)

Claims 42-45. (Withdrawn)